Doctors who perform this procedure

Edit search filters
close

Narrow your search

  1. Find a doctor whose last name begins with the letter A
  2. There are no doctors whose last name begins with the letter B
  3. There are no doctors whose last name begins with the letter C
  4. There are no doctors whose last name begins with the letter D
  5. There are no doctors whose last name begins with the letter E
  6. There are no doctors whose last name begins with the letter F
  7. There are no doctors whose last name begins with the letter G
  8. There are no doctors whose last name begins with the letter H
  9. There are no doctors whose last name begins with the letter I
  10. There are no doctors whose last name begins with the letter J
  11. There are no doctors whose last name begins with the letter K
  12. There are no doctors whose last name begins with the letter L
  13. There are no doctors whose last name begins with the letter M
  14. There are no doctors whose last name begins with the letter N
  15. There are no doctors whose last name begins with the letter O
  16. There are no doctors whose last name begins with the letter P
  17. There are no doctors whose last name begins with the letter Q
  18. There are no doctors whose last name begins with the letter R
  19. There are no doctors whose last name begins with the letter S
  20. There are no doctors whose last name begins with the letter T
  21. There are no doctors whose last name begins with the letter U
  22. There are no doctors whose last name begins with the letter V
  23. There are no doctors whose last name begins with the letter W
  24. There are no doctors whose last name begins with the letter X
  25. There are no doctors whose last name begins with the letter Y
  26. There are no doctors whose last name begins with the letter Z
Reset all filters

Displaying 1-1 out of 1 doctors available

  1. Karen S. Anderson, M.D., Ph.D.
    Areas of focus:

    Immunotherapy for breast cancer, HPV infection, Breast cancer, Pancreatic cancer, Ovarian cancer

Sept. 05, 2026
  1. FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer. U.S. Food and Drug Administration. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sacituzumab-govitecan-hziy-monotherapy-and-combination-pembrolizumab-first-line. Accessed Aug. 4, 2026.
  2. Immunotherapy for breast cancer. National Cancer Institute. https://www.cancer.gov/types/breast/treatment/immunotherapy. Accessed Aug. 4, 2026.
  3. Schmid P, et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. New England Journal of Medicine. 2024; doi:10.1056/NEJMoa2409932.
  4. Heater NK, et al. Current and future immunotherapy for breast cancer. Journal of Hematology & Oncology. 2024; doi:10.1186/s13045-024-01649-z.
  5. Immune checkpoint inhibitors. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors. Accessed Aug. 4, 2026.
  6. Cortes J, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. New England Journal of Medicine. 2022; doi:10.1056/NEJMoa2202809.
  7. Raghavendra AS, et al. Breast cancer brain metastasis: A comprehensive review. JCO Oncology Practice. 2024; doi:10.1200/OP.23.00794.
  8. Villacampa G, et al. Neoadjuvant immune checkpoint inhibitors plus chemotherapy in early breast cancer: A systematic review and meta-analysis. JAMA Oncology. 2024; doi:10.1001/jamaoncol.2024.3456.
  9. Verma S, et al. Immunotherapy and radiation therapy sequencing in breast cancer: A systematic review. International Journal of Radiation Oncology, Biology, Physics. 2024; doi:10.1016/j.ijrobp.2024.01.001.
  10. Madsen AMH, et al. Targeted treatment of metastatic triple-negative breast cancer: A systematic review. The Breast Journal. 2024; doi:10.1155/2024/9083055.
  11. Chemotherapy for breast cancer. National Cancer Institute. https://www.cancer.gov/types/breast/treatment/chemotherapy. Accessed Aug. 5, 2026.
  12. Medical review (expert opinion). Mayo Clinic. Sept. 2, 2026.

Related

Immunotherapy for breast cancer